OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Dhir on Diagnostic Challenges in Sarcoma

February 5th 2021

Aditi Dhir, MD, discusses the challenges of diagnosing patients with sarcoma.

Dr. Abramson on the FDA Approval of Liso-Cel in Refractory Large B-Cell Lymphoma

February 5th 2021

Jeremy S. Abramson, MD, discusses the FDA approval of lisocabtagene maraleucel in refractory large B-cell lymphoma.

Dr. Spencer on the Rationale to Evaluate Panobinostat in Multiple Myeloma

February 4th 2021

Andrew Spencer, MD, MBBS, FRACP, FRCPA, discusses the rationale to evaluate panobinostat in multiple myeloma.

Dr. Markman on the Need for Comparative Trials With PARP Inhibitors in Ovarian Cancer

February 3rd 2021

Maurie Markman, MD, discusses the need for comparative clinical trials with PARP inhibitors in ovarian cancer.

Dr. Meisel on Sequencing Considerations in First- and Second-Line HER2+ Breast Cancer

February 3rd 2021

Jane L. Meisel, MD, discusses sequencing considerations in the first- and second-line settings of HER2-positive breast cancer.

Dr. Dhakal on the Onset of CAR T-Cell Therapy–Induced CRS in Multiple Myeloma

February 3rd 2021

Binod Dhakal, MD, discusses the differences in onset of cytokine release syndrome with CAR T-cell therapies in multiple myeloma.

Dr. Gralow on the Integration on Precision Medicine Into Oncology

February 2nd 2021

Julie R. Gralow, MD, discusses the integration of precision medicine into oncology.

Dr. Hwu on the Uptake of Cellular Therapy in Oncology

February 2nd 2021

Patrick Hwu, MD, discusses the uptake of cellular therapy in the treatment of patients with cancer.

Dr. Shitara on Analyzing the Effects of Prior Therapy on TAS-102 in Gastric/GEJ Cancer

February 2nd 2021

Kohei Shitara, MD, discusses the rationale to analyze the effects of prior therapy on outcomes with TAS-102 in patients with metastatic gastric/gastroesophageal junction cancer.

Dr. Campbell on the Importance of Multidisciplinary Care in RCC

February 1st 2021

Matthew T. Campbell, MD, MS, discusses the importance of utilizing a multidisciplinary treatment approach in renal cell carcinoma.

Dr. Spigel Discusses Advances in Early-Stage Lung Cancer

February 1st 2021

David Spigel, MD, discusses advances in early-stage lung cancer treatment.

Dr. McKenzie on the Rationale for Concurrent Tissue and Liquid Biopsies in Lung Cancer

February 1st 2021

Andrew McKenzie, PhD, discusses the rationale to utilize concurrent tissue- and liquid-based biopsies in lung cancer.

Dr. Murphy on the Utility of Pazopanib Plus SBRT in Pediatric Sarcoma

January 29th 2021

Erin Murphy, MD, discusses the utility of pazopanib plus stereotactic body radiation therapy in pediatric sarcoma.

Dr. Howard Sharp on the Importance of Racial and Ethnic Diversity in Pediatric Clinical Trials

January 29th 2021

Katianne M. Howard Sharp, PhD, discusses the importance of racial and ethnic diversity in clinical trials for pediatric patients with cancer.

Dr. Moore on the Use of Preventive Anastrozole Versus Tamoxifen in DCIS

January 28th 2021

Halle Moore, MD, discusses the use of preventive anastrozole versus tamoxifen in ductal carcinoma in situ.

Dr. Matsen on the Effects of Decreased Breast Cancer Screening in the COVID-19 Era

January 28th 2021

Cindy B. Matsen, MD, discusses the potential effects of the decrease in screening for patients with breast cancer during the coronavirus disease 2019 pandemic.

Dr. Callander on the Expanding Role of Belantamab Mafodotin in Multiple Myeloma

January 28th 2021

Natalie S. Callander, MD, discusses the expanding role of belantamab mafodotin-blmf in multiple myeloma.

Dr. Kumar on Treatment Selection Considerations in Multiple Myeloma

January 27th 2021

Shaji K. Kumar, MD, discusses treatment selection considerations in multiple myeloma.

Dr. Fonseca on the Shift Toward Frontline Quadruplet Regimens in Multiple Myeloma

January 26th 2021

Rafael Fonseca, MD, discusses the shift toward frontline quadruplet regimens in multiple myeloma.

Dr. Ailawadhi on Potential Combination Strategies in Multiple Myeloma

January 26th 2021

Sikander Ailawadhi, MD, discusses potential combination strategies with selinexor and belantamab mafodotin-blmf in multiple myeloma.